IMBECU   20882
INSTITUTO DE MEDICINA Y BIOLOGIA EXPERIMENTAL DE CUYO
Unidad Ejecutora - UE
congresos y reuniones científicas
Título:
Effect of Olaparib in combination with Doxorubicin on MDA-MB-231 breast cancer cell line.
Autor/es:
DE PAOLA, MATILDE; VARGAS ROIG, LAURA M; REDONDO, ANALIA L; DE CAMPOS NEBEL, MARCELO; SOTTILE, MAYRA L; GOMEZ, LAURA C
Reunión:
Simposio; Buenos Aires Breast Cancer Symposium BA-BCS 2021; 2021
Resumen:
Breast cancer (BC) is the leading cause of cancer death in women in Argentina. Anthracycline-based regimens represent the major chemotherapeutic agents used in BC treatment. However, chemotherapy resistance development and adverse effects are still a challenge for the oncology. PARP1 is a key DNA repair protein mainly involved in base excision repair. Last years, PARP inhibitors (PARPi) have been approved for the treatment of BRCA-mutated BC. The aim of this work was to determine the effect of the PARPi olaparib on the sensitivity to doxorubicin in a BRCA-proficient BC cell line.